NasdaqCM - Nasdaq Real Time Price • USD
Oramed Pharmaceuticals Inc. (ORMP)
As of 11:11 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 2 | -- |
| Avg. Estimate | 0.02 | -0.02 | -0.26 | 0 |
| Low Estimate | 0.02 | -0.02 | -0.41 | 0 |
| High Estimate | 0.02 | -0.02 | -0.11 | 0 |
| Year Ago EPS | -0.08 | -0.03 | 0.14 | -0.26 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 2 | 1 |
| Avg. Estimate | 500k | 500k | 1.3M | -- |
| Low Estimate | 500k | 500k | 600k | -- |
| High Estimate | 500k | 500k | 2M | -- |
| Year Ago Sales | 750k | 674k | 1.34M | 1.3M |
| Sales Growth (year/est) | -33.30% | -25.80% | -3.00% | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.26 | -0.1 | -0.08 | -0.12 |
| EPS Actual | -0.08 | -0.03 | -0.08 | 0.33 |
| Difference | 0.18 | 0.07 | 0 | 0.45 |
| Surprise % | 69.20% | 70.00% | 0.00% | 375.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.02 | -0.02 | -0.26 | 0 |
| 7 Days Ago | 0.02 | -0.02 | -0.26 | -1.08 |
| 30 Days Ago | 0.02 | -0.02 | -0.26 | -1.08 |
| 60 Days Ago | 0.02 | -0.02 | -0.26 | -1.08 |
| 90 Days Ago | 0.02 | -0.02 | -0.11 | -1.08 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ORMP | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 125.00% | -- | -- | 1.30% |
| Next Qtr. | 33.30% | -- | -- | 10.60% |
| Current Year | -285.70% | -- | -- | 5.10% |
| Next Year | -- | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.21% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Canaccord Genuity: Hold to Hold | 5/17/2023 |
| Downgrade | HC Wainwright & Co.: Buy to Neutral | 1/17/2023 |
| Downgrade | Canaccord Genuity: Buy to Hold | 1/12/2023 |
| Maintains | Aegis Capital: Buy | 5/16/2022 |
| Initiated | Cantor Fitzgerald: Overweight | 2/18/2022 |
| Maintains | HC Wainwright & Co.: Buy | 11/30/2021 |
Related Tickers
ENLV Enlivex Therapeutics Ltd.
1.3400
+5.51%
BLRX BioLineRx Ltd.
0.6427
-5.08%
CGEN Compugen Ltd.
1.9800
+4.76%
PLUR Pluri Inc.
4.9900
-0.40%
EVGN Evogene Ltd.
0.6876
+4.99%
CANF Can-Fite BioPharma Ltd.
1.9601
-1.01%
IFRX InflaRx N.V.
1.4100
+2.92%
ATXI Avenue Therapeutics, Inc.
0.1289
-0.92%
RVPH Reviva Pharmaceuticals Holdings, Inc.
3.1400
+1.62%
ENTX Entera Bio Ltd.
2.0700
+0.98%